Pulmocide is a unique biopharmaceutical company with a mission to treat common acute and chronic respiratory tract infections associated with serious complications and devastating effects on patients’ quality of life. Unlike currently available treatments for fungal and viral infections in the lung, Pulmocide’s innovative approach to drug development provides targeted delivery to the lung so that infections can be treated with minimal unwanted systemic effects. The Pulmocide team has an extensive track record in the discovery and development of novel inhaled medicines for respiratory indications, with particular expertise in the identification of compounds with optimal characteristics for lung delivery.